FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.
What happened
FDA reviewed the company’s website, https://bestchinesemedicines.com, in September 2026. FDA found that the labeling for five products made claims to treat diseases and conditions, including tumors, high blood pressure, arrhythmias, Covid-19 symptoms, and arthritis, so FDA treated the products as drugs. FDA said no approved applications are in effect for them, making them unapproved new drugs.
What FDA found
FDA says Dissolve Mass Stasis Breaker is an unapproved new drug because its webpage says it helps dissipate nodules, palpable masses, and tumors, and no FDA-approved application is in effect for it.
FD&C Act sections 301(d), 201(g)(1), 201(p), 505(a); 21 U.S.C. 331(d), 321(g)(1), 321(p), 355(a)FDA says Gynostemma Leaf (Penta) Jiao Gu Lan is an unapproved new drug because its webpage and blog say it lowers LDL cholesterol, raises HDL cholesterol, controls blood pressure, and restores healthy blood pressure, and no FDA-approved application is in effect for it.
FD&C Act sections 301(d), 201(g)(1), 201(p), 505(a); 21 U.S.C. 331(d), 321(g)(1), 321(p), 355(a)FDA says Wenxin Keli is an unapproved new drug because its webpage says it is for arrhythmias, palpitations, shortness of breath, chest pain, ventricular contractions, atrial premature beats, and other cardiovascular disease, and no FDA-approved application is in effect for it.
FD&C Act sections 301(d), 201(g)(1), 201(p), 505(a); 21 U.S.C. 331(d), 321(g)(1), 321(p), 355(a)FDA says Lianhua Qingwen Capsules is an unapproved new drug because its webpage says it is a popular treatment for symptoms related to Covid-19 and is kept on hand during cold and flu season and periods of increased respiratory concerns, and no FDA-approved application is in effect for it.
FD&C Act sections 301(d), 201(g)(1), 201(p), 505(a); 21 U.S.C. 331(d), 321(g)(1), 321(p), 355(a)FDA says Duhuo Jisheng Wan is an unapproved new drug because its webpage says it is for lower back pain, joint pain, rheumatoid arthritis, diabetic neuropathy, and osteoarthritis, and no FDA-approved application is in effect for it.
FD&C Act sections 301(d), 201(g)(1), 201(p), 505(a); 21 U.S.C. 331(d), 321(g)(1), 321(p), 355(a)
What FDA wants
FDA tells the company to send a written response within 15 business days to FDAAdvisory@fda.hhs.gov with the corrective steps taken, steps to prevent recurrence, and supporting documents, using reference number 738556. FDA also says to promptly address the violations.
Who should pay attention
- online sellers of herbal products
- retailers or marketplaces listing Chinese medicine formulas
- consumers who rely on disease-treatment claims on product websites
This is a summary. Read the original letter on fda.gov.